Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tobira Therapeutics reverse merges with Regado Biosciences

Executive Summary

Regado Biosciences Inc., a public anti-thrombotics company, and private biotech Tobira Therapeutics Inc. (hepatic and infectious diseases) reverse merged; the resulting entity will carry the Tobira name, be led by Tobira's CEO Laurent Fischer, MD, and be owned 68% by Tobira's existing stockholders (with Regado holding the rest). Regado will nominate three representatives to the board.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Reverse Acquisition

Related Companies